Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 1
1988 3
1989 5
1990 3
1991 5
1992 3
1993 2
1994 2
1995 1
1996 5
1998 4
1999 2
2000 6
2001 4
2002 3
2003 2
2004 2
2005 1
2006 5
2007 5
2008 16
2009 12
2010 20
2011 19
2012 21
2013 26
2014 30
2015 29
2016 25
2017 31
2018 33
2019 26
2020 32
2021 29
2022 25
2023 27
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Mills AM, Rizzardini G, Ramgopal MN, Osiyemi OO, Bogner JR, Hagins DP, Paredes R, Reynes J, Rockstroh JK, Carr A, Su FH, Klopfer SO, Eves K, Plank RM, Correll T, Fox MC. Mills AM, et al. Among authors: rizzardini g. Lancet HIV. 2024 May 8:S2352-3018(24)00030-4. doi: 10.1016/S2352-3018(24)00030-4. Online ahead of print. Lancet HIV. 2024. PMID: 38734016
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM, Rizzardini G, Orrell C, Afani A, Calmy A, Oka S, Hinestrosa F, Kumar P, Tebas P, Walmsley S, Grandhi A, Klopfer S, Gendrano I, Eves K, Correll TA, Fox MC, Kim J. Molina JM, et al. Among authors: rizzardini g. Lancet HIV. 2024 May 8:S2352-3018(24)00031-6. doi: 10.1016/S2352-3018(24)00031-6. Online ahead of print. Lancet HIV. 2024. PMID: 38734015
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024.
Moschese D, Raccagni AR, Giacomelli A, Piralla A, Rossotti R, Raimondi A, Tesoro D, Vezzosi L, Gulletta M, Clementi N, Venturelli S, Benardon S, Ricaboni D, Bernacchia D, Mancon A, Rovida F, Attanasi F, Cereda D, Gismondo MR, Gori A, Rizzardini G, Antinori S, Baldanti F, Marzano AV, Marchetti G, Castelli F, Castagna A, Nozza S, Mileto D; Mpox Lombardy study group. Moschese D, et al. Among authors: rizzardini g. Clin Infect Dis. 2024 Apr 4:ciae184. doi: 10.1093/cid/ciae184. Online ahead of print. Clin Infect Dis. 2024. PMID: 38573320 No abstract available.
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus.
Mancon A, Raccagni AR, Gagliardi G, Moschese D, Rizzo A, Giacomelli A, Cutrera M, Salari F, Bracchitta F, Antinori S, Gori A, Rizzardini G, Castagna A, Gismondo MR, Nozza S, Mileto D. Mancon A, et al. Among authors: rizzardini g. Emerg Microbes Infect. 2024 Dec;13(1):2337666. doi: 10.1080/22221751.2024.2337666. Epub 2024 Apr 14. Emerg Microbes Infect. 2024. PMID: 38572513 Free PMC article.
First imported case of Candida auris infection in Milan, Italy: genomic characterisation.
Rimoldi SG, Nodari R, Rizzo A, Tamoni A, Longobardi C, Pagani C, Grosso S, Salari F, Galimberti L, Olivieri P, Rizzardini G, Catena E, Antinori S, Comandatore F, Castelli A, Gismondo MR. Rimoldi SG, et al. Among authors: rizzardini g. Infection. 2024 Apr 1. doi: 10.1007/s15010-024-02232-x. Online ahead of print. Infection. 2024. PMID: 38557967 Free article.
Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy.
Piralla A, Mileto D, Rizzo A, Ferrari G, Giardina F, Gaiarsa S, Petazzoni G, Bianchi M, Salari F, Bracchitta F, Sammartino JC, Ferrari A, Gagliardi G, Mancon A, Fenizia C, Biasin M, Rovida F, Paolucci S, Percivalle E, Lombardi A, Micheli V, Nozza S, Castagna A, Moschese D, Antinori S, Gori A, Bonfanti P, Rossotti R, D'Arminio Monforte A, Attanasi F, Tirani M, Cereda D, Baldanti F, Gismondo MR; MPXV Lombardy Network. Piralla A, et al. Travel Med Infect Dis. 2024 May-Jun;59:102698. doi: 10.1016/j.tmaid.2024.102698. Epub 2024 Mar 29. Travel Med Infect Dis. 2024. PMID: 38556220 Free article.
Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M, Scaglione G, Fassio F, Galli L, Lai A, Bergna A, Gabrieli A, Tarkowski M, Ventura CD, Colombo V, Cordier L, Bernasconi D, Corbellino M, Dedivitiis G, Borghetti S, Visigalli D, Sollima S, Casalini G, Rizzardini G, Gori A, Antinori S, Riva A, Schiavini M. Colaneri M, et al. Among authors: rizzardini g. Virol J. 2024 Mar 20;21(1):68. doi: 10.1186/s12985-024-02333-x. Virol J. 2024. PMID: 38509536 Free PMC article.
430 results